Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is headquartered in West Chester, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
Previous Symbol
CUSIPN/A
Phone484-453-3300
Debt
Debt-to-Equity RatioN/A
Current Ratio40.27
Quick Ratio40.27
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-4,450,000.00
Net MarginsN/A
Return on Equity-35.15%
Return on Assets-26.46%
Miscellaneous
Employees11
Outstanding Shares25,700,000
Market Cap$257.99 million
OptionableNot Optionable
Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions
What is Verrica Pharmaceuticals' stock symbol?
Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."
How were Verrica Pharmaceuticals' earnings last quarter?
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) posted its earnings results on Wednesday, November, 7th. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.03. View Verrica Pharmaceuticals' Earnings History.
When is Verrica Pharmaceuticals' next earnings date?
What price target have analysts set for VRCA?
3 brokerages have issued 1-year target prices for Verrica Pharmaceuticals' stock. Their forecasts range from $24.00 to $35.00. On average, they expect Verrica Pharmaceuticals' share price to reach $28.3333 in the next twelve months. This suggests a possible upside of 182.2% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals.
What is the consensus analysts' recommendation for Verrica Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals.
Has Verrica Pharmaceuticals been receiving favorable news coverage?
News stories about VRCA stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are some of Verrica Pharmaceuticals' key competitors?
Some companies that are related to Verrica Pharmaceuticals include Deciphera Pharmaceuticals (DCPH), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Crinetics Pharmaceuticals (CRNX), Athenex (ATNX), ImmunoGen (IMGN), Lexicon Pharmaceuticals (LXRX), Dicerna Pharmaceuticals (DRNA), Alder Biopharmaceuticals (ALDR), Intra-Cellular Therapies (ITCI) and Aptinyx (APTX).
Who are Verrica Pharmaceuticals' key executives?
Verrica Pharmaceuticals' management team includes the folowing people:
- Mr. Ted White, Pres, CEO & Director (Age 53)
- Mr. Chris Degnan, Chief Financial Officer (Age 38)
- Ms. Linda S. Palczuk, Chief Operating Officer (Age 56)
- Mr. Joe Bonaccorso, Chief Commercial Officer (Age 54)
- Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 46)
When did Verrica Pharmaceuticals IPO?
(VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.
When did Verrica Pharmaceuticals' lock-up period expire?
Verrica Pharmaceuticals' lock-up period expired on Wednesday, December 12th. Verrica Pharmaceuticals had issued 5,000,000 shares in its IPO on June 15th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Since the end of Verrica Pharmaceuticals' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Who are Verrica Pharmaceuticals' major shareholders?
Verrica Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (2.51%), Vanguard Group Inc. (1.14%), Vanguard Group Inc (1.14%), BlackRock Inc. (0.99%), Kornitzer Capital Management Inc. KS (0.84%) and FIL Ltd (0.70%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning and Ted White. View Institutional Ownership Trends for Verrica Pharmaceuticals.
Which major investors are selling Verrica Pharmaceuticals stock?
Which major investors are buying Verrica Pharmaceuticals stock?
VRCA stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., Point72 Asset Management L.P., Kornitzer Capital Management Inc. KS, Gilder Gagnon Howe & Co. LLC, Asymmetry Capital Management L.P. and Bank of New York Mellon Corp. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning and Ted White. View Insider Buying and Selling for Verrica Pharmaceuticals.
How do I buy shares of Verrica Pharmaceuticals?
Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Verrica Pharmaceuticals' stock price today?
One share of VRCA stock can currently be purchased for approximately $10.04.
How big of a company is Verrica Pharmaceuticals?
Verrica Pharmaceuticals has a market capitalization of $257.99 million. Verrica Pharmaceuticals employs 11 workers across the globe.
What is Verrica Pharmaceuticals' official website?
How can I contact Verrica Pharmaceuticals?
Verrica Pharmaceuticals' mailing address is 10 North High Street Suite 200, West Chester PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]
MarketBeat Community Rating for Verrica Pharmaceuticals (NASDAQ VRCA)
MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
